

IN THE CLAIMS:

Please cancel claims 1-13, without prejudice, and add the following new claims:

*Sub*  
*14* --14. A method of preventing or controlling cataract or <sup>*after cataract formation*</sup> ~~cataract-like disorders~~ in the eye of a mammalian subject which comprises the step of administering to the subject an effective amount of one or more inhibitors of TGF $\beta$ .--

*D* --15. The method according to claim 14 wherein the one or more inhibitors of TGF $\beta$  are selected from proteins, <sup>*glycoproteins*</sup> ~~glycoproteins~~ and proteoglycans.--

*A* --16. The method according to claim 15 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.--

--17. The method according to claim 15 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.--

--18. The method according to claim 15 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.--


--19. An ophthalmological formulation comprising one or more inhibitors of TGF $\beta$  in an ophthalmologically acceptable carrier but excluding conventional pharmaceutically acceptable carriers.--

--20. The ophthalmological formulation according to claim 19 wherein the one or more inhibitors of TGF $\beta$  are selected from proteins, glycoproteins and proteoglycans.--

--21. The ophthalmological formulation according to claim 20 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.--

--22. The ophthalmological formulation according to claim 20 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.--

--23. The ophthalmological formulation according to claim 20 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.--

--24. A method of preventing or controlling aftercataract formation in the eye of a mammalian subject following lens implant surgery which comprises the step of implanting in the eye of the subject a lens coated with one or more TGF $\beta$  inhibitors.--

--25. The method according to claim 24 wherein the one or more inhibitors of TGF $\beta$  are selected from proteins, glycoproteins and proteoglycans.--

--26. The method according to claim 25 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.--

--27. The method according to claim 25 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.--

--28. The method according to claim 25 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.--

--29. A lens implant comprising a coating, the coating including one or more TGF $\beta$  inhibitors.--

--30. The lens implant according to claim 29 coated with one or more TGF $\beta$  inhibitors selected from proteins, glycoproteins and proteoglycans.--

--31. The lens implant according to claim 30 wherein the protein inhibitors of TGF $\beta$  are selected from antibodies and peptide growth factors.--

--32. The lens implant according to claim 30 wherein the glycoprotein inhibitors of TGF $\beta$  are selected from  $\alpha_2$ -macroglobulin, laminin and collagen.--

--33. The lens implant according to claim 30 wherein the proteoglycan inhibitors of TGF $\beta$  are selected from decorin, heparan sulfate proteoglycans and biglycan.--

--34. The use of inhibitors of TGF $\beta$  in the manufacture <sup>of an</sup> ~~and~~ ophthalmological formulation for preventing or controlling cataract or cataract-like disorders.--